Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental...

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Neurodevelopmental Pediatrics

Background:

• Postnatal steroid use in preterm infants for chronic lung disease (CLD) presents a complex risk-benefit profile.
• Hydrocortisone and dexamethasone are commonly considered treatments, but their long-term neurodevelopmental effects require careful evaluation.

Purpose of the Study:

• To review the existing literature on postnatal hydrocortisone treatment for CLD in preterm infants.
• To specifically assess the impact of hydrocortisone on long-term neurodevelopmental outcomes compared to other steroids like dexamethasone.

Main Methods:

• Systematic literature review of published quantitative evidence.
• Focus on studies examining neurodevelopmental outcomes following postnatal steroid administration for CLD.

Main Results:

• Current evidence does not demonstrate a significant advantage of hydrocortisone over dexamethasone regarding long-term neurological outcomes.
• Quantitative data is insufficient to definitively establish superiority of one steroid over the other for neurodevelopmental impact.

Conclusions:

• The choice between hydrocortisone and dexamethasone for CLD in preterm infants requires further investigation.
• A consensus on whether hydrocortisone should replace dexamethasone may be needed based on the best available evidence, pending randomized comparisons.